BR112022023519A2 - Tkis de egfr para uso no tratamento de câncer de pulmão de células não pequenas - Google Patents

Tkis de egfr para uso no tratamento de câncer de pulmão de células não pequenas

Info

Publication number
BR112022023519A2
BR112022023519A2 BR112022023519A BR112022023519A BR112022023519A2 BR 112022023519 A2 BR112022023519 A2 BR 112022023519A2 BR 112022023519 A BR112022023519 A BR 112022023519A BR 112022023519 A BR112022023519 A BR 112022023519A BR 112022023519 A2 BR112022023519 A2 BR 112022023519A2
Authority
BR
Brazil
Prior art keywords
lung cancer
small cell
cell lung
treatment
tkis
Prior art date
Application number
BR112022023519A
Other languages
English (en)
Portuguese (pt)
Inventor
Rukazenkov Yuri
Ghiorghiu Serban
Borellini Flavia
Mann Helen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112022023519A2 publication Critical patent/BR112022023519A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022023519A 2020-05-27 2021-05-26 Tkis de egfr para uso no tratamento de câncer de pulmão de células não pequenas BR112022023519A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063030372P 2020-05-27 2020-05-27
PCT/EP2021/063992 WO2021239786A1 (en) 2020-05-27 2021-05-26 Egfr tkis for use in the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
BR112022023519A2 true BR112022023519A2 (pt) 2022-12-20

Family

ID=76181131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023519A BR112022023519A2 (pt) 2020-05-27 2021-05-26 Tkis de egfr para uso no tratamento de câncer de pulmão de células não pequenas

Country Status (14)

Country Link
US (3) US20210369709A1 (enExample)
EP (1) EP4157267B1 (enExample)
JP (1) JP2023529812A (enExample)
KR (1) KR20230017830A (enExample)
CN (2) CN115776889A (enExample)
AU (1) AU2021279171A1 (enExample)
BR (1) BR112022023519A2 (enExample)
CA (1) CA3183434A1 (enExample)
DK (1) DK4157267T3 (enExample)
FI (1) FI4157267T3 (enExample)
IL (1) IL298216A (enExample)
MX (1) MX2022014903A (enExample)
TW (1) TW202216149A (enExample)
WO (1) WO2021239786A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022526159A (ja) 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
WO2024118611A2 (en) * 2022-11-28 2024-06-06 Brown University Treatment of epidermal growth factor receptor mutant non-small cell lung cancer
CN117298116A (zh) * 2023-08-08 2023-12-29 江苏晨泰医药科技有限公司 盐酸佐利替尼制剂
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (zh) 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
EP3661519A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor

Also Published As

Publication number Publication date
JP2023529812A (ja) 2023-07-12
CA3183434A1 (en) 2021-12-02
IL298216A (en) 2023-01-01
AU2021279171A1 (en) 2023-02-02
EP4157267A1 (en) 2023-04-05
CN115776889A (zh) 2023-03-10
DK4157267T3 (da) 2026-08-03
US20210369709A1 (en) 2021-12-02
WO2021239786A1 (en) 2021-12-02
KR20230017830A (ko) 2023-02-06
US20240423978A1 (en) 2024-12-26
US20250325543A1 (en) 2025-10-23
MX2022014903A (es) 2023-01-04
EP4157267B1 (en) 2026-07-08
CN122376595A (zh) 2026-07-14
TW202216149A (zh) 2022-05-01
FI4157267T3 (fi) 2026-08-12

Similar Documents

Publication Publication Date Title
MX2022014903A (es) Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
MX2009007987A (es) Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
EA202192552A1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого
PE20220807A1 (es) Nuevos inhibidores de egfr
Huang et al. Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells
BRPI0606839B8 (pt) Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
JOP20220182A1 (ar) مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
Sankarapandian et al. A review on tyrosine kinase inhibitors for targeted breast cancer therapy
BR112018074941A2 (pt) combinações farmacêuticas
EA202091841A1 (ru) Осимертиниб для применения для лечения немелкоклеточного рака легкого
MX2020012540A (es) Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales.
MX2024011959A (es) Inhibidores de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr) junto con un inhibidor de la akt para el tratamiento del cáncer.
MX2022008874A (es) Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
CA3259492A1 (en) COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
Hou et al. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models
BR112014004762A2 (pt) métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
EP4097140A4 (en) USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCERS WITH NRG1 GENE FUSIONS
Yue et al. OA 16.04 efficacy and safety of erlotinib vs vinorelbine/cisplatin as adjuvant therapy for stage IIIA EGFR mutant NSCLC patients
BR112021024139A2 (pt) Composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo
JOP20230211A1 (ar) علاج أنواع السرطان التي تفتقر إلى الطفرات المنشطة لمستقبل عامل نمو البشرة (egfr)
HK40126841A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
HK40126792A (en) Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
IL318241A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
Laktionov et al. Prospects for the development of adjuvant therapy for non-small cell lung cancer